Abstract
Abstract Objective:The aim of the study was to evaluate the safety and therapeutic efficacy of autologous dendritic cells co-cultured with cytokine-induced killer cells (DC-CIK) for the treatment of lung cancer patients. Methods:In the present study, we recruited a group of 40 lung cancer patients after surgery registered in the Biotherapy Center during 2005-2011 and randomly divided patients into two groups: Twenty patients treated with DC-CIK therapy as the treatment group and the other twenty patients served as controls.Subjects were administrated with 1×106 units of IL-2 daily for 5 days before mononuclear cell isolation from peripheral blood. For the treatment group, after primary tumors were removed by surgery, 1-3 doses of DCs and CIKs were perfused via peripheral veins. The immunologic function,short-term therapeutic effects, 5-years overall survival rate (OS), and disease free survival rate (DFS) were compared between the two groups.In addition, the peripheral blood samples were extracted from all patients before and after DC-CIK therapy,analyzed for T cell subsets by flow cytometry,and the intracellular cytokines of T cells were detected simultaneously. Results:OS for 1, 3, and 5 years of DC-CIK therapy group were 100%, 88%, and 88% respectively which contrasted with 78%,66%, and 25% in the control group. DFS 1, 3, and 5 years of DC-CIK therapy groups were 100%, 85%,65% respectively compared to 73%,58%, 23% in the control groups. Although there were no changes in the subsets of T cells in peripheral blood before and after DC-CIK therapy, the intrace1lular cytokines IFN-γ,IL-2,IL-4, and IL-6 of the immune cells were noticeably improved in the treatment group. Conclusion:DC-CIK therapy is a potential effective therapeutic modality to improve OS and DFS in post-surgical lung cancer patients. Citation Format: Daiqing Gao, Changyou Li, Peng Zhao, Xiaofang Wei, Xihe Xie, Weihong Sun, Qingming Guo, Danni Zhu, Tianyi Gao, Aris T. Alexandrou, Jian Jian Li. The clinical effects of dendritic cell and cytokine-induced killer cell therapy for lung cancer after surgery. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2812. doi:10.1158/1538-7445.AM2014-2812
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.